The drug combination should be a first line of treatment, UCLA researchers say.
A combination approach could be new strategy for people with advanced cancers.
Scientists from 22 institutions, including UCLA, call for early diagnosis, prevention and treatment to reduce the risk of chronic diseases.
Research brief: The new method, using robotics, will speed up how researchers test for therapies that block the metabolism of non-small-cell lung cancer tumors.
The finding could lead to better treatments for leukemia and other blood diseases.
Report from Web of Science Group identifies researchers in 21 fields whose work was most often referenced by other papers.
UCLA graduate student Cody Aros is helping make science and medicine more inclusive for LGBTQ-identifying people.
Funds from California’s stem cell agency will support research on a blinding eye disease, cancer and an immune disorder.
The funds will help advance work in diagnosis, prognosis and treatment of the disease
The study demonstrates that PET imaging can be used to read mitochondrial activity in lung tumors.
The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of what is known as killer T cells, the foot soldiers of the immune system.
In most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after remission, and the cancer can recur.
When reviewers were subspeciality-trained, misclassification rates were the lowest.
The finding suggests that predicting how a person’s cancer will evolve may lie in their inherited genetic material.
The approach could eventually be useful not only for treating cancer, but also for lipid metabolism-related conditions like diabetes.
The researchers’ goal was to create a therapy that would permanently boost the body’s ability to naturally produce more iNKT cells.
Innovative technology improves visualization of a patient’s anatomy.
The study results have the potential to establish a new standard for using this method to actively monitor prostate cancer.
The prominent cancer researcher is honored for his invention of the breast cancer drug Herceptin.
The invention relies in part on another UCLA invention, photonic time stretch.
Of mice that received high doses of radiation, nearly all that received a compound developed by UCLA scientists survived.
Research brief: UCLA researchers developed a drug delivery system that can break through the blood-brain barrier.
The system could help reduce errors in differentiating ductal carcinoma in situ, a noninvasive type of cancer, from breast atypia.
The observation helps explain why, as people age, the prostate tends to grow, leading to an increased risk for cancer and other conditions.
Research brief: The study recommends that the new procedure should become the standard of care.